Our overall objective of the project is the implementation of single-cell sequencing techniques in the context of a multiomics approach that includes bulk WGS, RNAseq, and total/phospho proteomics to investigate pediatric and AYA HGG biology. Analyses will focus on biospecimens collected across multiple surgical events and/or specimens collected from patients defined as extreme short survivors. Analyses will evaluate dynamic changes across time in the bulk expression and genomics as well as the microenvironment, and the immunologic status of tumors . We hypothesize that such integrated multi-omic analysis will lead to etter understanding of these diseases and the development of more effective therapeutics to improve outcomes for patients.
What are the goals of this project?
The goals of this project are to generate single-cell sequencing data of cancer cells, infiltrating immune cells and non-immune microenvironment in pediatric and AYA high-grade gliomas and epigenetic profiling of matched samples by EPIC (850K) arrays or whole genome bisulfite sequencing.
What is the impact of this project?
Our overall hypothesis is that a focus on single-cell techniques, the microenvironment, and the immunologic status of tumors and matched preclinical models will lead to a better understanding of these diseases and the development of more effective therapeutics to improve outcomes for patients.
Why the CBTN request is important to this project?
The Children's Brain Tumor Network provides a unique resource of samples, genomic data and longitudinal clinical data.
The Children's Brain Tumor Network contributed to this project by providing tissue samples.
Adam Resnick, PhD
Adam Resnick is the Director of Data Driven Discovery in Biomedicine (D3b) at Children’s Hospital of Philadelphia (CHOP) responsible for leading a multidisciplinary team to build and support a scalable, patient-focused healthcare and educational discovery ecosystem on behalf of all children. He i
Children’s Hospital of Philadelphia
UCSF Benioff Children's Hospital
Michael Prados, MD
Michael Prados began his career in Neuro-Oncology as a Fellow at the University of California San Francisco in 1985. Following a two year training program, he was recruited to the Faculty in 1988 and has remained at UCSF since that time, and holds the Charles B Wilson Chair in Neurosurgery. His c
UCSF Benioff Children's Hospital
Michelle Monje, MD, PhD
Michelle Monje, MD, PhD joined the faculty at Stanford University in 2011 as an Assistant Professor of Neurology & Neurological Sciences. Following her undergraduate degree in biology at Vassar College, Dr. Monje received her MD and PhD in Neuroscience from Stanford University. She then compl
Lucile Packard Children's Hospital Stanford
High-grade glioma/astrocytoma (WHO grade III/IV)
High-grade Gliomas (HGG) in children nearly always result in a dismal prognosis. Although novel therapeutic approaches are currently in development, preclinical testing has been limited, due to a lack of pediatric specific HGG preclinical models. These models are needed to help test the effective
Children's Brain Tumor Network Pediatric Brain Tumor Proteomics Pilot
Pediatric brain tumors are the leading cause of disease related death in children. Major factors contributing to treatment failures for children with brain tumors include: i) the lack of comprehensive molecular description of the disease and an associated dearth of integration of the tumors’ biol
Craniopharyngioma, Medulloblastoma, HGG, Atypical teratoid/rhabdoid tumor (AT/RT), LGG, Ependymoma, Ganglioglioma, DNET, Schwannoma